Skip to Main content Skip to Navigation
Journal articles

Lipoproteins LDL versus HDL as nanocarriers to target either cancer cells or macrophages

Abstract : In this work, we have explored natural unmodified low- and high-density lipoproteins (LDL and HDL) as selective delivery vectors in colorectal cancer therapy. We show in vitro in cultured cells and in vivo (NanoSPECT/CT) in the CT-26 mice colorectal cancer model that LDLs are mainly taken up by cancer cells, while HDLs are preferentially taken up by macrophages. We loaded LDLs with cisplatin and HDLs with the heat shock protein-70 inhibitor AC1LINNC, turning them into a pair of “Trojan horses” delivering drugs selectively to their target cells as demonstrated in vitro in human colorectal cancer cells and macrophages, and in vivo. Coupling of the drugs to lipoproteins and stability was assessed by mass and raman spectrometry analysis. Cisplatin vectorized in LDLs led to better tumor growth suppression with strongly reduced adverse effects such as a renal or liver toxicity. AC1LINNC vectorized into HDLs induced a strong oxidative burst in macrophages and innate anti-cancer immune response. Cumulative anti-tumor effect was observed for both drug-loaded lipoproteins. Altogether, our data show that lipoproteins from patient’s blood can be used as natural nanocarriers allowing cell specific targeting, paving the way toward more efficient, safer and personalized use of chemo-and immunotherapeutic drugs in cancer
Document type :
Journal articles
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-03036574
Contributor : Samir Messaoudi <>
Submitted on : Wednesday, December 2, 2020 - 5:00:45 PM
Last modification on : Monday, January 4, 2021 - 11:18:37 AM
Long-term archiving on: : Wednesday, March 3, 2021 - 8:01:30 PM

File

140280.1-20201130102846-covere...
Files produced by the author(s)

Identifiers

Citation

Tarik Hadi, Christophe Ramseyer, Thomas Gautier, Pierre-Simon Bellaye, Tatiana Lopez, et al.. Lipoproteins LDL versus HDL as nanocarriers to target either cancer cells or macrophages. JCI Insight, American Society for Clinical Investigation, 2020, 5 (24), pp.e140280. ⟨10.1172/jci.insight.140280⟩. ⟨hal-03036574⟩

Share

Metrics

Record views

215

Files downloads

230